Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Subacute or Chronic Pain Pain: a Randomized Controlled Trial
RecruitingNot applicableNCT06350786
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study aims to evaluate whether the reduction of the daily morphine equivalent dose (MED) in patients with subacute and chronic pain can be decreased with an open-label placebo (OLP) intervention in comparison to an electronic monitoring (EM) control group. The participants will receive the intervention (OPL or EM) over the duration of six weeks. Diverse psychological and health measures will be assessed with questionnaires over the course of the intervention. Furthermore, evaluation outcomes, qualitative outcomes and safety outcomes will be assessed. It is hypothesized that the OLP-intervention group in comparison to the EM-control group will have a significantly lower consumption of MED over the course of the study. Furthermore, this study aims to evaluate whether the OLP intervention can reduce opioid withdrawal symptoms in comparison to the control group.
Study details
- Official title
- Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Subacute or Chronic Pain Pain: a Randomized Controlled Trial
- Conditions
- Chronic Pain
- Subacute Pain
- Interventions
- Other: P-Dragees blue Lichtenstein, Placebo dragees
- Other: Control group (EM)
- Sponsor
- Cosima Locher
- Collaborators
- Brown University; University of Basel
- Organization
- University of Zurich
- Start date
- 2024-06-12
- Primary completion
- 2026-09-30
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Switzerland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Signed Informed Consent * ≥ 18 years of age * German speaking * Pain lasting ≥ 4 weeks, including subacute pain (4-12 weeks) and chronic pain (\>12 weeks) * Opioid medication for pain management for ≥ 4 weeks * Oral intake of opioid medication * Motivation for opioid reduction * Participants have a primary treating physician who performs the reduction of the opioid medication * Having access to a computer or tablet with an email-account Exclusion Criteria: * Having psychotic symptoms * Suicidality * Cognitive impairment to everyday life * Planned surgery within the next two months that is expected to affect opioid intake * Known illegal drug or harmful alcohol consumption * Intolerance of the ingredients of the placebo pill (e.g., lactose, sucrose, corn-starch) * Serious health problems that make study participation impossible * Simultaneous participation in other studies with investigational drugs or pain specific interventions
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06350786